A Visual Summary of BioJapan 2026

- Gateways to the Asian market -



YOKOHAMA · JAPAN

World Business Forum

BioJapan 2026
YOKOHAMA

IRMJ
Regenerative Medicine Japan 2026

healthTECH JAPAN 2026

BioJapan Organizing Committee / JTB Communication Design, Inc.

CONTENTS

1 Overview 1-2

2 Opening Ceremony 2

3 Keynote Lectures 3

4 Organizer Seminars 4–9

- I. Foundations for Bioindustry Growth
- II. Biomanufacturing & Food Tech
- III-1. Medicine, Pharmaceuticals & Regenerative Medicine – Innovation in New Drugs
- III-2. Medicine, Pharmaceuticals & Regenerative Medicine – Innovation in Regenerative Medicine
- IV. HealthTech

5 Investment Forum 10


6 Sponsor Seminars 11

7 Exhibition 12

8 Partnering 13

9 Networking 14

10 Partner Events 14



PACIFICO Yokohama
1 Chome-1-1 Minatomirai, Nishi Ward, Yokohama, Kanagawa 220-0012

1 Overview

BioJapan / Regenerative Medicine Japan / healthTECH JAPAN 2026 was held over three days, from **Wednesday, October 7 to Friday, October 9, 2026, at PACIFICO Yokohama**. First launched in 1986, the event marked its 28th edition and its **40th anniversary this year**. It was organized by the BioJapan Organizing Committee, consisting of eight bio-related organizations, and JTB Communication Design, Inc.


Throughout the three days, the venue was filled with energy as global opinion leaders, business executives, researchers, and investors gathered from around the world. The event provided a dynamic forum for exchanging ideas, building valuable connections, and exploring opportunities for future partnerships.

22,835
Visitors

1,820
Companies

233
Seminars & Presentations

660
Companies from overseas



27,813
One-on-one meetings

3,352
Partnering Participants


Global Participation

40 Countries and Regions Represented

Australia	Kazakhstan
Austria	Luxembourg
Belgium	Netherlands
Canada	New Zealand
China	Norway
Croatia	Philippines
Cyprus	Poland
Czech Republic	Portugal
Denmark	Russia
Estonia	Saudi Arabia
Finland	Singapore
France	South Korea
Germany	Spain
Greece	Sweden
Hong Kong	Switzerland
Hungary	Taiwan
India	Thailand
Ireland	Turkey
Israel	United Kingdom
Italy	United States

*Excluding Japan


Country / Region Rankings




*This data shows only the top 10. *Number of participating companies

The number of Participants

Exhibitor · Partnering Companies



One-on-one Partnering Meetings



2 Opening Ceremony

On behalf of the organizers, Dr. **Minoru Yoshida**, Chairman of the BioJapan Organizing Committee (Chairman, Japan Bioindustry Association), delivered the opening address, expressing his gratitude to the distinguished guests and participants.

Congratulatory remarks were delivered by the following distinguished guests.

Mr. **Hiroo Inoue**, Director-General for Commerce and Service Industry Policy, Ministry of Economy, Trade and Industry (METI); Mr. **Kouichi Andou**, Assistant Minister for Pharmaceutical Industry Promotion, Ministry of Health, Labour and Welfare of Japan (MHLW); Ms. **Tomoko Ikuta**, Deputy Assistant Minister/Deputy Director-General, Research Promotion Bureau and Higher Education Policy, Science and Technology Policy Cooperation, Ministry of Education, Culture, Sports, Science and Technology-Japan (MEXT); Dr. **Osamu Okuda**, Committee on Bioeconomy, Keidanren (Japan Business Federation); Mr. **Chris McDonald** MP, Minister for Science, Innovation and Investment of the United Kingdom; H.E. Mr. **Daniel Naumovas**, Vice-Minister of Health of the Republic of Lithuania. The ceremony was also attended by Ms. **Corin Robertson**, incoming British Ambassador to Japan; H.E. Dr. **Aurelijus Zykas**, Ambassador of the Republic of Lithuania to Japan; and Mr. **Shigeyuki Shiratori**, Deputy Mayor of Kawasaki City.



Minoru Yoshida
Chairman of the BioJapan Organizing Committee (Chairman, Japan Bioindustry Association)



Hiroo Inoue
Director-General for Commerce and Service Industry Policy, Ministry of Economy, Trade and Industry (METI)



Kouichi Andou
Assistant Minister for Pharmaceutical Industry Promotion, Ministry of Health, Labour and Welfare of Japan (MHLW)



Tomoko Ikuta
Deputy Assistant Minister/Deputy Director-General, Research Promotion Bureau and Higher Education Policy, Science and Technology Policy Cooperation, Ministry of Education, Culture, Sports, Science and Technology-Japan (MEXT)



Osamu Okuda
Committee on Bioeconomy, Keidanren (Japan Business Federation)



Chris McDonald
Minister for Science, Innovation and Investment of the United Kingdom



Daniel Naumovas
Vice-Minister of Health of the Republic of Lithuania



Corin Robertson
Incoming British Ambassador to Japan



Aurelijus Zykas
Ambassador of the Republic of Lithuania to Japan



Shigeyuki Shiratori
Deputy Mayor of Kawasaki City

3 Keynote Lectures

Keynote Lecture 1



Co-creating the Future of Japan's Biopharmaceutical Ecosystem

Asuka Miyabashira
Chairman of Japan Pharmaceutical Manufacturers Association

Dr. Miyabashira noted that biopharmaceuticals account for approximately 60% of approvals for drugs containing new active ingredients. In Japan, however, the number of pipeline programs held by emerging biotech companies is small compared with the United States and China, and the country's domestic self-sufficiency rate for biopharmaceuticals stands at only 14%. JPMA has submitted recommendations to the government built on three pillars: revitalizing drug discovery capabilities, building more resilient domestic manufacturing capacity, and sustaining and strengthening the talent base. In the public-private investment roadmap under the Japan Growth Strategy, both drug discovery and advanced medicine, and synthetic biology and biotechnology, were ranked among the top five areas by scale of public-private investment. She emphasized that people are the key to the drug discovery ecosystem Japan aims to build, and that the next wave of innovation will come from the talent Japan develops connecting and co-creating across organizations and fields.

Keynote Lecture 2



From the Chōshū Five to DeepMind: 160 years of UK-Japan life sciences partnership

Geraint Rees
Vice-Provost (Research, Innovation & Global Engagement), University College London (UCL)

Professor Rees traced 160 years of UK-Japan collaboration in the life sciences, beginning with the "Chōshū Five," who secretly left Japan from Yokohama in 1863 to study at UCL. He structured his talk around three stages: people build trust, institutions sustain it, and ecosystems provide speed and scale. As examples, he cited UCL's 14-year drug discovery alliance with Eisai Co., Ltd. in neurodegenerative diseases and the establishment of an ophthalmic AI company with Topcon Corporation. He noted that the UK faces challenges in securing funding and in adopting innovations in healthcare, while Japan faces the problem of "drug loss," in which drugs approved overseas are never developed or launched in Japan. The two countries, he argued, therefore complement each other. Identifying dementia, cell and gene therapy, and AI-driven drug discovery as priority areas, he called for joint applications under Horizon Europe through 2027.

Keynote Lecture 3



Toward a Bioeconomy: Sumitomo Chemical's Strategy in the Green, Red, and White Areas

Nobuaki Mito
Representative Director & President, SUMITOMO CHEMICAL COMPANY, LIMITED

Dr. Mito explained that Sumitomo Chemical's businesses span four domains: Food (Green), ICT (White), Healthcare (Red), and Environment (Gray). The company's business strategy is built on a "hybrid of chemistry and biotechnology." In the Green domain, it launched Sumitomo Biorational Company, which is developing mycorrhizal fungi, biostimulant formulations, and feed additives for livestock. In the Red domain, Sumitomo Chemical is applying chemically synthesized therapeutic oligonucleotides to genome editing therapies. It is also drawing on its cell culture technologies to develop iPS cell-derived products for patients with Parkinson's disease. In the White and Gray domains, the company is developing bio-based aromatic super engineering plastics and producing olefins from biomass. Sumitomo Chemical is also pursuing new value creation that combines chemistry and biotechnology, shifting from selling products toward providing solutions and experiences (koto-uri).

Keynote Lecture 4



New Drugs for Cancer, Neuro, and Aging

Christoph Westphal
Co-Founder & General Partner, Longwood Fund

Dr. Westphal described biopharmaceutical development as a continuous process that moves from academic research to company formation, early-stage clinical trials, partnerships with pharmaceutical companies, and commercialization, and he stressed that collaboration among experts from diverse fields is essential. He presented his firm's model as a venture capital investor: building companies around technologies spun out of universities and pharmaceutical companies, and nurturing them through early clinical development. He also emphasized the importance of generating returns on investment. Citing the success of several RNAi companies he has founded, he identified scientific discovery, large therapeutic effects, and outstanding people as the keys to launching a company. Using caloric restriction research as an example, he also explained the potential for drug discovery that could help prevent aging-related diseases.

4 Organizer Seminars

A total of **18 organizer seminars** were held. The organizer seminars are featured below.

I. Foundations for Bioindustry Growth

Progress and Prospects for Drug Discovery Incubation

Coordinator: Aya Kubota, Senior Fellow, Healthcare Media Unit, Nikkei Business Publications, Inc.; Director of the Board, Japan Bioindustry Association (JBA)
Toshio Asano, Chairman, Japanese Foundation for Cancer Research; President, Japan Bioindustry Association (JBA)
Hitoshi Nakagama, President, Japan Agency for Medical Research and Development (AMED)
Jay Park, Partner, McKinsey & Company, Inc. Japan
Stacy Feld, Global Head, External Scientific Innovation, Johnson & Johnson


Aya Kubota


Toshio Asano


Hitoshi Nakagama



Quantum Computing in Drug Discovery - From Promise to Implementation

Coordinator: Matt Terabe, Managing Director, Chief of Quantum Technology, Deloitte Tohmatsu Group
Kazuhiro Sugie, Director of Innovation Policy and Quantum Industry Office, Innovation Policy Division, Innovation and Environment Policy Bureau, Ministry of Economy, Trade and Industry
Masahiro Horibe, Project Manager, Deputy Director and Executive Chief, Global Research and Development Center for Business by Quantum-AI technology, National Institute of Advanced Industrial Science and Technology
Ayumu Imai, Japan Country Manager, QuEra Computing Inc.
Atsushi Ohtsu, Director, Research Unit, Japanese Foundation for Cancer Research
Takao Suzuki, AVP, Head of Digital Transformation Unit, Chugai Pharmaceutical Co., Ltd.
Yoshitake Kitanishi, Associate Corporate Officer, VP, Data Science Department, Shionogi & Co., Ltd.


Matt Terabe


Masahiro Horibe


Ayumu Imai



From Clinical Trials to Investment Returns: Toward the Rebuilding of Bioecosystem in Japan

Coordinator: Daisuke Yoshizumi, Managing Director, General Industries Group Investment Banking, JPMorgan Securities Japan Co., Ltd.
Toshihiko Doi, Director, Hospital East, National Cancer Center
Yasuhiro Fujiwara, Chief Executive, Pharmaceuticals and Medical Devices Agency
Jonathan Hirsch, Co-Founder and Chief Strategy Officer, Paradigm Health, Inc.
Taku Achiwa, Chief Development Officer, A-SEEDS Co., Ltd.


Daisuke Yoshizumi


Toshihiko Doi


Yasuhiro Fujiwara

Note: Names are listed in order of presentation.

Biocluster Summit

Coordinator: Tsuneaki Sakata, President / Chairman, All Japan Bio-Community Liaison Committee / NPO Kinki-Bio-industry Development Organization
Minesh Lalla, Senior Business Development Manager, Business Ventures | Pathology and Nexomics, Peter MacCallum Cancer Centre
Els Verhulst, Science & Technology Counselor, FLANDERS INVESTMENT & TRADE
Janice Warkentin Steeves, President and CEO, Deep Tech Canada
Simon GUDIN, Head of International affairs, Lyonbiopole Auvergne Rhone Alps
Gabriel Flemming, Senior Manager/Lead Pharma and Medical Biotech, HEALTH MADE IN GERMANY at Germany Trade & Invest
Gianpaolo Bruno, Head of the Trade Promotion Section, Embassy of Italy - Tokyo
Marta Szczygieł, Head of Foreign Trade Office in Tokyo, Polish Investment & Trade Agency
Tiziana Rosa, Head of International Relations, Swiss Biotech Association
Sonia Chen, Deputy Director, Biotechnology and Pharmaceutical Industries Promotion Office (BPIPO), Ministry of Economic Affairs, Taiwan
Chris Molloy, CEO, The UK BioIndustry Association (BIA)
Fujita Tony, Managing Director, Biocom California


Tsuneaki Sakata


Minesh Lalla


Els Verhulst


Janice Warkentin Steeves


Simon GUDIN


Gabriel Flemming


Gianpaolo Bruno


Marta Szczygieł


Tiziana Rosa


Sonia Chen


Chris Molloy


Fujita Tony

II. Biomanufacturing & Food Tech

The Cutting Edge and Challenges of Bio-Manufacturing Technology

Coordinator: Yutaka Tamaru, Chairman / Professor, Working Group for New Resource Bioconversion / Green Goals Initiative, Green X-tech Research Center, Japan Bioindustry Association (JBA) / Tohoku University
Hendrik Waegeman, Head of Business Operations, Bio Base Europe Pilot Plant
Tsubasa Nakajima, Chief Analyst, Global Environment Dept., Policy Research & Consulting Division, Mitsubishi UFJ Research and Consulting Co., Ltd.
Motoaki Seki, Team Director, Center for Sustainable Resource Science, RIKEN
Mitsuo Umetsu, Chief Scientific Officer / Professor, RevolKa Ltd. / Tohoku University


Yutaka Tamaru


Hendrik Waegeman


Motoaki Seki

Strategies and Challenges for Accelerating the Social Implementation of Bio-Manufacturing

Coordinator: Masaru Utsunomiya, Executive Officer, Chief Technology Officer, Mitsubishi Chemical Corporation; Director of the Board, Japan Bioindustry Association (JBA) / Chair of the Social Implementation Working Group, Bio-Manufacturing Forum
Yoshitaka Yamamuro, Director, Bio-Industry Division, Commerce and Service Industry Policy Group, Ministry of Economy, Trade and Industry
Benjamin Yim, Senior Director, Business Development, Northeast Asia, Lummus Technology
Koichi Nakata, President, Research Association of Biomass Innovation for Next Generation Automobile Fuels


Masaru Utsunomiya


Yoshitaka Yamamuro


Koichi Nakata



Note: Names are listed in order of presentation.

Fermentation Beyond Borders: How Japanese FoodTech Is Transforming Global Bio-Manufacturing

Coordinator: Jun Ogawa, Professor, Graduate School of Agriculture, Kyoto University; Director of the Board, Japan Bioindustry Association (JBA)
Bruce Friedrich, Founder / President, The Good Food Institute
Shoko Asahina, Director, New Business and Food Industry Department, Ministry of Agriculture, Forestry and Fisheries
Shintaro Iwatani, Corporate Executive General Manager, Research & Business Planning Dept., Ajinomoto Co., Inc.
Tetsushi Kawai, General Manager, Chitose Laboratory Corp.
Yuji Suzuki, Representative Director, President and CEO, bitBiome, Inc.


Jun Ogawa


Bruce Friedrich


Shoko Asahina



III-1. Medicine, Pharmaceuticals & Regenerative Medicine – Innovation in New Drugs

New Modalities × AI-Driven Drug Discovery: Current Landscape and Future

Coordinator: Shumpei Ishikawa, Professor, Department of Public Health, Graduate School of Medicine, The University of Tokyo; Chief, Division of Clinical Oncologic Pathology, Exploratory Oncology Research & Clinical Trial Center (EPOC), National Cancer Center Japan; Director of the Board, Japan Bioindustry Association (JBA)
Ryu Ogawa, Chief Innovation Officer, MOLCURE Inc.
Sohei Oyama, Head of Biological Technology Dept., Research Division, Chugai Pharmaceutical Co., Ltd.
Masataka Hasegawa, Senior Manager, Process Engineering & Technology Center, FUJIFILM Corporation
Mizue Hisano, Scientific Business Consultant, Biologics Business Unit, Genedata AG


Shumpei Ishikawa


Sohei Oyama


Masataka Hasegawa

NAMs Transforming Drug Discovery R&D-Data-Driven Life Science and Industrial Implementation

Coordinator: Kohei Tsumoto, Professor, Department of Bioengineering, School of Engineering, The University of Tokyo; Director of the Board, Japan Bioindustry Association (JBA)
Hirokazu Sugiyama, Professor, Department of Chemical System Engineering, The University of Tokyo
Yuzuru Ito, Professor, Institute of Life and Environmental Sciences, University of Tsukuba
Akiko Ishii-Watabe, Director, Division of Biological Chemistry and Biologicals, National Institute of Health Sciences
Yumi Cleary, Clinical Pharmacometrician, Quantitative Clinical Pharmacology, Pharmaceutical Sciences, Roche Pharma Research and Early Development, Roche Innovation Center Basel, Switzerland, F. Hoffmann-La Roche Ltd.


Kohei Tsumoto


Hirokazu Sugiyama


Akiko Ishii-Watabe



Note: Names are listed in order of presentation.

Bringing Rare Disease Therapies to Patients: Challenges and Opportunities in Japan

Coordinator: Yasushi Kajii, R&D Japan Region Head, R&D Global Regions, Takeda Pharmaceutical Company Limited; Director of the Board, Japan Bioindustry Association (JBA)
Keiichiro Suzuki, Specially Designated Professor, Institute for Advanced Co-Creation Studies, The University of Osaka
Hiroya Kuwahara, Associate Professor, Neurology and Neurological Science / Nucleotide and Peptide Drug Discovery Center, Institute of Science Tokyo
Raymond Chan, Partner, McKinsey & Company, Inc. Japan
Charles Soong, Associate Partner, McKinsey & Company, Inc.
Yoshitsugu Aoki, Director, Department of Molecular Therapy, National Institute of Neuroscience, National Center of Neurology and Psychiatry
Daisuke Fujii, Technical Counsellor, National Healthcare Policy Counsellor, Cabinet Office


Yasushi Kajii


Raymond Chan


Daisuke Fujii

Powering Resilient Biologics Manufacturing - A Tri Sector Collaboration of Pharma, CDMOs, and Suppliers

Coordinator: Takashi Kaminagayoshi, Senior Director, Head of Drug Substance Operations, Biotherapeutics Process Development, Pharmaceutical Sciences (R&D), Takeda Pharmaceutical Company Limited
Shinya Takuma, Vice President, Head of Manufacturing Technology Division, Chugai Pharmaceutical Co., Ltd.
Hisatoshi Ito, FUJIFILM Toyama Chemical Co., Ltd.
Kosuke Takenaka, Principal Scientist, Pharmaceutical Science, Takeda Pharmaceutical Company Limited
Sadahiro Kanazawa, Head of Process Solutions, Merck Ltd.


Takashi Kaminagayoshi


Shinya Takuma


Sadahiro Kanazawa



Challenges and Prospects for Promoting the Use of Domestic Manufacturing Infrastructure for Biopharmaceuticals

Coordinator: Kazuhisa Uchida, Professor, Graduate School of Science, Technology and Innovation, Kobe University
Kentaro Tanaka, Assistant Director, Bio-Industry Division, Ministry of Economy, Trade and Industry
Hirokazu Shimoda, Senior Director, Japan Agency for Medical Research and Development (AMED)
Taishiro Nakagawa, Chairperson, Policy Subcommittee, Biopharmaceuticals Committee, Japan Pharmaceutical Manufacturers Association (JPMA) (Kyowa Kirin Co., Ltd.)
Akira Kase, Executive Director Corporate Vice President General Manager Bio CDMO Division, Bio Business Division, FUJIFILM Toyama Chemical Co., Ltd.


Kazuhisa Uchida


Kentaro Tanaka


Hirokazu Shimoda



Note: Names are listed in order of presentation.

Conditional and Time-Limited Approval in Japan: Overview of Approved Products and System Utilization

Coordinator: Yoshihiro Yoshikawa, Director, Forum for Innovative Regenerative Medicine; Senior Executive Officer, President, Division of Regenerative Medicine, NIPRO CORPORATION
Kazumi Sawaguchi, Corporate Officer, Regulatory Affairs, Quality Assurance and Compliance Dept., PharmaBio Corporation
Kenji Yoshida, Regenerative and Cellular Medicine Office, Sumitomo Pharma Co., Ltd.
Yoko Sano, Elevidys Lifecycle Leader, Specialty Lifecycle Management Dept., CHUGAI PHARMACEUTICAL CO., LTD.
Kazuhisa Senshu, Executive Advisor, Terumo Corporation
Masaki Kasai, Review Director, Office of Cellular and Tissue-based Products, Pharmaceuticals and Medical Devices Agency


Yoshihiro Yoshikawa


Kazumi Sawaguchi


Kenji Yoshida



The Current Landscape of the CDMO Ecosystem Driving the Industrialization of Regenerative Medicine, Cell Therapy, and Gene Therapy in Japan

Coordinator: Koichi Nakao, Former Director, Forum for Innovative Regenerative Medicine; Chairman, Takara Bio Inc.
Yoshitaka Yamamuro, Director, Bio-Industry Division, Commerce and Service Industry Policy Group, Ministry of Economy, Trade and Industry
Monika Pema, Senior Manager (MSAT-Process Validation), Cell & Gene Technology Division, AGC Biologics SPA
Katsuhito Hashizume, Senior Executive Officer, Takara Bio Inc.
Kazuto Yamada, President and CEO, Japan Tissue Engineering Co., Ltd.
Hirokazu Shimoda, Senior Director, Japan Agency for Medical Research and Development (AMED)


Koichi Nakao


Yoshitaka Yamamuro


Monika Pema



Toward Improving Regenerative Medicine and Gene Therapy Services under the Act on the Safety of Regenerative Medicine

Coordinator: Kunihiko Suzuki, Chair, Specific Processed Cells Committee (ASRM Committee), Forum for Innovative Regenerative Medicine
Hisaya Tomori, Director, Office for Promotion of Regenerative Medicine, Research and Development Policy Division, Health Policy Bureau, Ministry of Health, Labour and Welfare
Kohji Nishida, Professor and Chairman, Department of Ophthalmology, Graduate School of Medicine, The University of Osaka
So Ra Park, President, Regenerative Medicine Acceleration Foundation
Daisuke Noguchi, MEDINET Co., Ltd. / Forum for Innovative Regenerative Medicine (FIRM)


Kunihiko Suzuki


Kohji Nishida


So Ra Park



Note: Names are listed in order of presentation.

IV. HealthTech

Creating Healthier Living Environments: The Promise of Zero-Order Prevention

Coordinator: Takuko Sawada, Vice-Chair, Shionogi & Co., Ltd.; Director of the Board, Japan Bioindustry Association (JBA)
Katsunori Kondo, Professor, Department of Community Building for Well-being, Center for Preventive Medical Sciences, Chiba University
Nobuhiko Horioka, Director, Health Promotion Division, Health and Living Environment Bureau, Ministry of Health, Labour and Welfare
Yasuhisa Ano, Associate Director, CGO Office, Eisai Co., Ltd.
Søren Brunak, Professor, Dept. of Public Health, University of Copenhagen


Takuko Sawada


Katsunori Kondo


Nobuhiko Horioka



Healthcare Deep Tech for Pre-Disease and Super-Aging Societies: Startups Advancing Diagnostics, Drug Discovery, and Digital Biomarkers

Coordinator: Tsuyoshi Sekitani, Professor, SANKEN, The University of Osaka
Mika Mizunuma, COO, Craif, Inc.
Shunichi Kashida, Founder, CBO, xFOREST Therapeutics Co., Ltd.
Tina Sampath, CEO, Cumulus Neuroscience Limited
Zahid Latif, VP Global Innovation, Shionogi B.V.
Maria Koufali, Life Sciences Industry Director, National Institute for Health and Care Research (NIHR)


Tsuyoshi Sekitani


Shunichi Kashida


Maria Koufali



Enhancing Well-being Through Food: The Third Function of Foods in Strengthening Health Resilience

Coordinator: Daisuke Fujiwara, Senior Executive Officer (R&D Strategy) and President of Research & Development Division, Kirin Holdings Company, Limited; Director of the Board, Japan Bioindustry Association (JBA)
Moderator: Kenta Migimatsu, Nippon Television
Yuji Kuroiwa, Governor, Kanagawa Prefectural Government
Kinuko Abe, Managing Director, The Japan Dietetic Association
Hidekazu Kawakubo, Japan Alliance of Health Food Associations
Tamotsu Imanishi, Director, Office of Health and Nutrition Labelling, Food Labelling Division, Consumer Affairs Agency


Daisuke Fujiwara


Yuji Kuroiwa


Tamotsu Imanishi



Note: Names are listed in order of presentation.

5 Investment Forum

Launched in 2025, the **Investment Forum** has quickly become one of BioJapan's flagship programs.

Japan's drug discovery startup ecosystem has been growing rapidly, supported by substantial government funding, including major government-backed funding programs open to international venture capital firms. As a result, investment by overseas VCs in Japanese drug discovery startups has increased significantly.

Against this backdrop, BioJapan established the **Investment Forum** as a platform to bring together drug discovery startups from across Asia, including Japan, and international venture capital firms. Conducted entirely in English, the **Investment Forum** provides a unique opportunity for startups and investors to connect directly, exchange ideas, and explore investment opportunities.

This year, the **Investment Forum** once again served as an important meeting place, facilitating connections between numerous venture capital firms and drug discovery startups.

VC

UTokyoIPC
Innovation Platform for The University of Tokyo

AN VENTURE PARTNERS

FTI
FAST TRACK INITIATIVE

saisei ventures

UTEC

Public Institution

JETRO
Japan External Trade Organization

AMED
Japan Agency for Medical Research and Development

Pharmaceutical Company

astellas

Ecosystem Builder


NINEJP

iPark / JBA
Japan Bioindustry Association



Pitch Session by NINEJP


Panel Session by JETRO


Panel Session by FTI



Pitch Session by iPark & JBA

6 Sponsor Seminars

In addition to the organizer seminars, **71 official sponsor seminars** were held, bringing the total number of seminars to a record high.

The sponsor seminars provided an opportunity for participating companies and organizations to introduce their latest initiatives and activities. They also helped raise their visibility and strengthen their corporate image, while creating opportunities for new partnerships and collaborations. This year, a particularly large number of seminars were hosted by sponsors from overseas.

The sponsor seminars are categorized below by subject area, along with the names of the sponsors who presented them.

Pharma

Bayer, Boehringer Ingelheim, CHUGAI (Roche Group), Roche, CELLTRION, CSL, Lilly, Johnson & Johnson, MERCK, SERVIER (moved by you)

Biotech / Drug Discovery Technology / Services

Acro Biosystems, Alloy Therapeutics, AXAM (Harness Biology, Empower Discovery, 25th Anniversary), BIOCYTOGEN, labcorp, Lonza, NCCJ (National Cancer Center Japan), SARTORIUS, Sino Biological, Syneos Health, TaKaRa

CMO / CDMO

ANEMOCYTE, DAI-DAN, 再生CDMO補助金, SAMSUNG BIOLOGICS, XDC (The Bioconjugation Leader)

Medical Institution / Hospital / CRO / SMO

4DIN, EPS Corporation, EPS BioPath, YUROGEN

Medical Machinery / Device

Harro Höfliger (ALL YOU NEED), NGK (Surprising Ceramics.), skan, TERUMO (BLOOD AND CELL TECHNOLOGIES)

Other Manufacturing

TOPPAN

IT, Electronics / Digital

patsnap, SCIENCE AID

Academia / Research Institute

AIST (Create the Future, Collaborate Together), GteX (Green Technologies of Excellence), KYOTO-iCAP, 京都大学 KYOTO UNIVERSITY, RIKEN

Incubation facility management

CIC, OSAKA LIFE SCIENCE NEXUS, KASHIWA-NO-HA LIFE SCIENCE FRONTIER, iPark

Government / Public Institution

KBIC, LIFE SCIENCE NATION (Connecting Products, Services & Capital), Japan Agency for Medical Research and Development, 神奈川県, NEDO (New Energy and Industrial Technology Development Organization), JST Japan Science and Technology Agency

Association / Biocluster

三井不動産 MITSUI FUDOSAN, LINK-J, JPMA

Foreign Government Agency

Australian Government, Australian Trade and Investment Commission; FLANDERS INVESTMENT & TRADE


Support Services (Accelerator/Consulting, etc.)

CITELINE | Evaluate, DARK HORSE CONSULTING GROUP

7 Exhibition

The exhibition featured **1,198 exhibitors**, up from 1,134 at the previous edition, with a total of **937 booths**, compared with 917 last year. A total of **22,835 people** attended the event, and the exhibition halls were bustling with activity throughout the three days.





40th Anniversary Commemorative Exhibition

To celebrate BioJapan's 40th anniversary, a commemorative exhibition featuring a series of panels was presented on the Main Stage.








JAPAN HEALTHCARE VENTURE SUMMIT 2026

In one area of the BioJapan exhibition hall, the **Ministry of Health, Labour and Welfare** hosted the 10th edition of the **Japan Healthcare Venture Summit**, bringing together a total of 126 exhibitors, including healthcare startups and supporting organizations such as venture capital firms, core clinical research hospitals, and R&D institutions. Throughout the three days, exhibitors also gave pitch presentations and took part in panel discussions in the exhibition hall, attracting large and engaged audiences.





8 Partnering

A total of **3,352 participants** took part in the partnering program, up from 3,073 in 2025. Of these, **1,036 came from overseas**, compared with 946 the previous year. The number of participating companies also increased to **1,820**, up from 1,568 in 2025. A total of **27,813 business meetings** were held, compared with 25,498 in the previous year.

This year, 216 partnering spaces were provided, including private meeting rooms and tables for business meetings. Major pharmaceutical companies also set up their own dedicated meeting spaces, where they held numerous business discussions.



Standard Partnering Rooms






Private Meeting Rooms




Refreshment Area



Open Partnering Tables



- Drug discovery Technologies / Services
- Pharma
- Academia / Institute
- CMO / CDMO
- Medical Examination Facility/ CRO / SMO
- Medical / Diagnosis / Research devices
- Support Services (Accelerator/Consulting/ Legal/Patent Office/Technology Transfer/ Staffing/Translation, etc.)
- Chemical / Materials / Fibers
- Others



- Business development / Licensing
- R&D/Technology
- Management
- Sales
- Consultant / Coordinator
- Planning / Research / PR / Marketing
- Others

9 Networking

Welcome Reception (Day 1)

On the evening of Day 1, a welcome reception was held at PACIFICO Yokohama North. Following the introduction of the winners of the Japan Bioindustry Awards and Bioindustry Research Awards, Dr. **Toshio Asano**, President of the Japan Bioindustry Association (JBA), delivered the opening remarks, followed by a toast by Dr. **Toshiharu Furukawa**, Minister for Digital Transformation. The reception was attended by a large gathering of participants from Japan and around the world and was a great success.


Toshio Asano


Welcome Reception


Toshiharu Furukawa

Partnering Party (Day 2)

On the evening of Day 2, networking parties for participants and organizers were held at Anniversaire Minatomirai Yokohama, a nearby event venue. The entire venue was reserved exclusively for the occasion, with different floors featuring dedicated areas for the Japan Healthcare Venture Summit, BioJapan, Regenerative Medicine Japan, and healthTECH JAPAN. A BioJapan tradition, the **World Band**, made up of musically talented JBA staff and members of JBA member companies, took the stage for a live performance. Overseas participants, including some familiar faces who return year after year, joined in the singing and playing. The evening offered a different kind of networking from the business meetings held during the day, giving participants a chance to connect on a more personal level through music and shared enjoyment. It was a lively and memorable evening for everyone.


Partnering Party


World Band Live

10 Partner Events

Starting this year, events held in the area around BioJapan during BioJapan Week were designated as official BioJapan Partner Events. BioJapan and the partner event organizers collaborated on promotional activities in advance of the event, helping to raise awareness and attract more participants to both. This initiative created valuable synergies and benefits for all involved.

1. EU-Japan Biotech & Pharma Partnering Conference 2026

Mon, Oct 5 9:30-18:45 @ Kita-ku, Osaka — Osaka Prefectural Government, EU-Japan Centre for Industrial Cooperation, Enterprise Europe Network (EEN)

2. Poland Biotechnology Business Seminar

Tue, Oct 6 10:00-12:40 @ Meguro, Tokyo — Embassy of the Republic of Poland in Tokyo, Polish Investment and Trade Agency (PAIH) Tokyo Office

3. Japan-Taiwan Pharmaceutical Supply Chain Resilience Cooperation and Partnering Event

Tue, Oct 6 14:00-16:30 @ Minato Mirai, Yokohama — BPIPO, DCB, Taiwan Bio

4. GLOBAL LIFE SCIENCE SESSION 2026

Tue, Oct 6 15:00-18:00 @ Nihonbashi, Tokyo — Life Science Innovation Network Japan (LINK-J)

5. Striving for Better Innovation, Better Investment, and Embracing Technology in Drug Research & Development

Tue, Oct 6 18:00-21:00 @ Minato Mirai, Yokohama — Connektia

6. German Regenerative Medicine Networking Reception

Wed, Oct 7 17:00-20:00 @ Minato Mirai, Yokohama — Berlin Partner for Business and Technology

7. Pitching Stars - Global Startup Night | BIO JAPAN 2026 WEEK

Thu, Oct 8 18:45-21:00 @ Minato Mirai, Yokohama — iCONM in collaboration with BioLabs


EU-Japan Biotech & Pharma Partnering Conference 2026


Global Life Science Session 2026


Pitching Stars - Global Startup Night | BIO JAPAN 2026 WEEK_ iCONM in collaboration with BioLabs

BioJapan 2027 YOKOHAMA

Regenerative Medicine Japan 2027

healthTECH JAPAN 2027

2027 Event Overview

Date: Oct. 13 Wed. – 15 Fri., 2027

Venue: PACIFICO Yokohama

Call for Exhibitors

https://jcd-expo.jp/en/

■ Contact

BioJapan Secretariat (c/o JTB Communication Design)

3 Chome-23-1 Shiba, Minato City, Tokyo 105-0014

biojapan@jtbcom.co.jp

Organizers |

● **BioJapan**

BioJapan Organizing Committee (Representative: Japan Bioindustry Association (JBA))

JTB Communication Design, Inc.

● **Regenerative Medicine Japan**

Forum for Innovative Regenerative Medicine (FIRM)

Japan Bioindustry Association (JBA)

JTB Communication Design, Inc.

● **healthTECH JAPAN**

Japan Bioindustry Association (JBA)

JTB Communication Design, Inc.

BioJapan Organizing Committee |

Japan Bioindustry Association (JBA)

Japan Association for Techno-innovation in Agriculture, Forestry and Fisheries (JATAFF)

Japan Biological Informatics Consortium (JBIC)

Japanese Association of Bioindustries Executives (JABEX)

Japan Pharmaceutical Manufacturers Association (JPMA)

NPO Kinki-Bio-industry Development Organization

Research Institute of Innovative Technology for the Earth (RITE)

Forum for Innovative Regenerative Medicine (FIRM)

BioJapan Organizing Committee Secretariat

c/o Japan Bioindustry Association (JBA)

Sapia Tower 8F, 1-7-12 Marunouchi,

Chiyoda-ku, Tokyo 100-0005, Japan

bd@jba.or.jp

Unauthorized reproduction prohibited.